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Abstract 
The benzodiazepine lorazepam is widely utilized in the treatment of elderly individuals with 
anxiety disorders and related conditions. Negative effects of acute lorazepam administration on 
cognitive performance, especially memory, have been reported in both previously untreated 
elderly and in individuals who have received short term (up to three weeks) treatment with 
therapeutic doses. However, it remains unclear if these adverse cognitive effects also persist after 
long-term use, which is frequently found in clinical practice. Cognitively intact elderly 
individuals (n=37) on long-term (at least three months) daily treatment with lorazepam were 
studied using a double-blind placebo-controlled cross-over study design. Subjects were 
administered their highest daily unit dose of lorazepam (0.25 – 3.00 mg) and placebo on different 
days, approximately 1 week apart in a random order, and were assessed on memory, 
psychomotor speed, and subjective mood states. Subjects had significantly poorer recall and 
slowed psychomotor performance following acute lorazepam administration. There were no 
significant effects on self-ratings of mood, sedation, or anxiety in the whole group, but secondary 
analyses suggested a differential response in subjects with GAD. Reduced recall and 
psychomotor slowing following acute lorazepam administration in long-term users reinforces the 
importance of cognitive toxicity as a clinical factor in benzodiazepine use. 
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Introduction 
Benzodiazepines (BZPs) are among the most widely prescribed drugs in the rapidly 
increasing elderly population. A number of surveys indicates that 13%-25% of community-
dwelling individuals (aged 65 or over) report current or recent BZP use (1-3). However, it is a 
concern that impairments in multiple cognitive domains (e.g., memory,  psychomotor 
performance) have been demonstrated consistently following acute doses of BZPs, in both 
healthy and anxious participants (2, 4-6). These impairments have been observed with 
lorazepam, which is generally prescribed in the elderly due in part to a lack of active metabolites, 
a relatively shorter elimination half-life, and a presumed better safety profile (3).  
In the elderly, administration of even a single dose of a BZP impairs performance (5, 7-11), and 
elderly individuals may show greater sensitivity than younger subjects to the adverse effects of 
BZPs on psychomotor performance (5, 7, 8) and memory (12).  Following chronic treatment 
with BZPs for 1-3 weeks, significant adverse effects can be observed following an acute dose – 
although partial tolerance may develop (4, 10, 12, 13). Unfortunately, clinical treatment often 
extends beyond 3 weeks (e.g., years), often increasing morbidity and mortality (3, 14).  
 In spite of the prevalence of long-term administration of BZPs in the elderly population, 
little is known about their cognitive toxicity under these conditions.  Several studies have 
examined the effects of acute doses of BZPs on performance in individuals on extended long-
term treatment (15-18). The findings suggest that acute administration of the patient’s usual daily 
unit dose may still result in significant impairment, even after several years of continuous BZP 
  
treatment. However, none of these studies included a placebo condition.  One study only 
examined saccadic eye movements and body sway (18) and another did not report psychiatric 
diagnoses (15).  Older participants were either not included (16) or were underrepresented (15, 
17, 18), questioning the relevance of these results in the elderly population. 
In the present study, we examined the effects of a single acute dose of lorazepam in elderly long-
term users treated with this drug for anxiety and related conditions. Memory and psychomotor 
performance was assessed and self-report measures of mood states and anxiety levels were 
obtained. We also determined the degree to which various factors (e.g., strength of daily unit 
dose, total daily dose, dosing frequency, and duration of treatment) contributed to the acute 
adverse effects. Because prolonged use of benzodiazepines is reported to be more prevalent in 
older individuals, especially women (19), we also examined if age and gender influenced the 
effects of an acute lorazepam challenge 
 
Methods 
Subjects: 
Thirty-seven psychiatric outpatients on long-term (between 3 and 252 months of 
treatment; median = 60 months) treatment with lorazepam for anxiety and related conditions 
were recruited for participation from outpatient psychiatric clinics, newspaper advertisements, 
and outreach efforts to senior citizen groups in the New York City area and Rockland County, 
NY. The study was conducted at the NYU-Bellevue General Clinical Research Center in New 
York City and the Nathan S. Kline Institute in Orangeburg, NY. Subjects ranged in age from 60 
  
– 91 years (M = 70.65 + 8.08). Absence of current DSM-IV psychotic illness, dementia, and 
current alcohol or substance abuse/dependence was also a required inclusion criterion. DSM-IV 
diagnoses were determined by clinical psychiatric interview and the Structured Clinical 
Interview (21). Subjects with severe neurological or medical illnesses, as determined by medical 
history, physical evaluation and routine laboratory tests, were excluded. All subjects were free of 
cognitive impairment, as determined by a score > 28 on the Mini Mental State Examination (23), 
an age-corrected score of at least 7 in the vocabulary subtest of the Wechsler Adult Intelligence 
Scale-Revised (24), and a score > 85 on the General Memory Index of the Wechsler Memory 
Scale-Revised (25). Other demographic characteristics and screening measures are presented in 
Table 1. Each participant was paid $200 for their participation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1. Demographics of the study population. The values represent group means with standard 
deviations in parentheses (WAIS-R = Wechsler Adult Intelligence Scale-Revised; WMS-R = Wechsler 
Memory Scale-Revised; BSRT = Buschke Selective Reminding Test). 
 
 
Characteristics 
    Total Sample 
    (N = 37) 
   Completer 
Group 
   (n = 31) 
    Non-
Completer 
Group (n = 6) 
Age, yrs 70.65 (8.08) 70.03 (7.82)  73.83 (9.43)  
Weight, lbs 169.26 (53.32) 174.14 (54.15) 145.67 (45.84) 
Education 15.27 (2.61) 15.18 (2.09) 15.67 (4.76) 
Sex, No. M/F 18/19 16/15 2/4 
Prescribed unit dose of  lorazepam, 
mg  
1.01 (0.55) 0.94 (0.55) 1.33 (0.52)  
Duration of lorazepam use, mos 82.08 (67.57) 79 (70.85) 98 (48.84) 
Total daily dose lorazepam, mg 1.43 (1.29) 1.21 (1.06) 2.5 (1.87) 
Hamilton Rating Scale for Anxiety 
(HAM-A) 
9.84 (5.59) 9.32 (5.55) 12.5 (5.47) 
Hamilton Rating Scale for 
Depression (HAM-D) 
9.46 (8.39) 9.03 (8.68) 11.67 (6.92) 
Mini-Mental Status Exam 29.24 (0.83) 29.42 (0.76) 28.33 (0.52) 
WAIS-R Vocabulary Score 13.11 (2.28) 13.23 (2.01) 12.5 (3.56) 
WMS-R Verbal Score 99.27 (15.37) 99.48 (16.00) 98.17 (12.72) 
WMS-R Visual Score 105.38(20.10) 104.13 (20.43) 111.83 (18.53) 
WMS-R General Memory Index 102.7 (13.99) 102.39 (13.67) 104.33 (16.87) 
BSRT Screening Total Recall 62.22 (13.78) 62.65 (13.64) 59.6 (16.01)  
 
Procedure: 
All participants provided written informed consent prior to participation. A double-blind, 
placebo-controlled, crossover study design on two different days, each separated by 
approximately 1 week, was used. Following diagnostic and screening evaluation, individuals 
participated in two five-hour experimental sessions on separate days, one-week apart. Subjects 
  
were randomly assigned to receive the sequence “lorazepam-placebo”, or “placebo-lorazepam”. 
Following a morning baseline assessment, each subject was either administered his/her highest 
daily unit dose of lorazepam as the challenge dose, or placebo. The highest daily unit doses 
ranged from 0.5 mg–3.0 mg lorazepam. Experimental sessions began at approximately 9:00 a.m. 
under non-fasting conditions. Lorazepam and placebo doses were prepared by the institutional 
pharmacy and dispensed at the experimental sessions by research staff.  The Buschke Selective 
Reminding Test (BSRT; 26, 27) and the Purdue Pegboard Test (PPT; 28, 29) tests, and both the 
Mood Rating Scale (MRS; 20) and the State-Trait Anxiety Inventory scale (STAI-S; 21) were 
administered at baseline, and again at 1, 2.5 and 5 hours following oral administration of the 
drug or placebo. Vital signs and blood samples were also obtained at each assessment point. The 
study was conducted in accordance with the Declaration of Helsinki. 
 
Plasma lorazepam determination:  
Blood samples for determination of plasma lorazepam levels were collected at baseline, 
and at 1, 2.5 and 5 hours post-drug administration. Quantitation of plasma drug levels was 
determined by electron-capture gas chromatography, as previously described (30).  
 
Neuropsychological Measures: 
The BSRT consists of a list of 16 nouns presented verbally to the subject at a rate of one 
word every two seconds. The subject is asked to recall as many words as possible and to indicate 
when no more can be recalled. After the initial presentation, the subject is presented only with 
  
those words that were not recalled on the immediately preceding trial, although they are asked to 
recall the entire list on each trial. Seven presentation and recall trials of the same list are given in 
immediate succession. Total Recall is defined as the total number of words correctly recalled 
across the seven learning trials.  
The PPT requires participants to place as many pegs as possible into a row of holes in a 30 sec 
period. Participants complete three pegboard trials that require 1) the sole use of a dominant 
hand, 2) the sole use of a non-dominant hand, and 3) both hands. The number of correctly 
inserted pegs are counted and recorded (score range = 0 – 25).  
The MRS is composed of 16 visual analogue scales, each with a 100 mm horizontal line 
anchored by opposing mood-descriptive adjectives, e.g., “Happy – Sad”. Participants are 
instructed to make a perpendicular mark along the horizontal axis. Marks closer to the midpoint 
(50 mm) are representative of neutral states, whereas marks closer to the anchor adjectives (0 
mm and 100 mm) represent increasing degrees of the indicated subjective mood state. The 16 
visual analogue scales of the MRS have been shown to be sensitive to the effects of acute 
psychopharmacological challenge (20).   
The STAI-S is a 20-item self-rating scale assessing affective and cognitive domains associated 
with anxiety as experienced in the present moment. Participants provide ratings on a 4-point 
scale ranging from 1 (“not at all”) to 4 (“very much so”) on items pertaining to subjective 
feelings of anxiety at the present time. Scores on the STAI-S range from 20 – 80, and the 
measure has been shown to be reliable (21). 
  
Scores on the Hamilton Depression (HAM-D) and Anxiety (HAM-A) scales were also obtained 
at baseline.  
Statistical Analysis: 
The comparisons between lorazepam and placebo over the 5 hours following their 
administration, with respect to all outcomes of interest, were based on mixed effects models 
analyses (31). The outcomes included lorazepam plasma levels, total recall on memory testing, 
motor performance, mood, and anxiety ratings. Time was considered a factor with 4 levels 
(baseline, and 1, 2.5 and 5 hours post-treatment administration). To account for the correlation 
between the repeated observations on a subject over the two conditions, random subject effects 
were included in the models. The outcomes over time were modeled as a function of time, 
treatment (i.e., drug vs placebo), and their interaction. A significant treatment-by-time interaction 
would indicate that the difference in the mean outcome under highest daily unit dose (challenge 
dose) of lorazepam vs. placebo depends on the time elapsed since treatment administration; such 
significant effects are followed by pair-wise comparisons between the means for the two 
conditions at each time point. If the interaction between treatment and time was not significant, 
the model was refit with only main effects for time and treatment, and the effects of treatment 
and of time were judged based on this model. Cohen’s d values are reported as indices of effect 
size for statistically significant F-tests and t-tests; these indices are computed as the ratio of the 
model based estimate of the difference in the means, divided by the standard deviation of the 
respective measure at baseline. 
  
To establish whether the challenge dose (ranging from 0.5 to 3.0 mg across study 
subjects) was associated with the magnitude of memory and psychomotor impairments following 
acute lorazepam administration, we modeled the outcome at 2.5 hours (i.e., time of peak effect) 
as a function of treatment, challenge dose and their interaction. We also explored whether the 
association between challenge dose and impairment depended on (i) duration of treatment, (ii) 
dosing frequency and (iii) total daily dose. This was done by modeling the outcome at time 2.5 
hours as a function of treatment, challenge dose, each of the factor (i), (ii) and (iii) and their 2- 
and 3-way interactions. A backward step-wise elimination procedure was employed to arrive at a 
final model, preserving the hierarchical principle. A significant 3-way (treatment)-by-
(covariate)-by-(challenge) dose interaction would indicate that the effect of lorazepam at 2.5 
hours after administration depends on the covariate and this dependence is different for different 
challenge doses; similarly, a significant 2-way (treatment)-by-(covariate) interaction would 
indicate that the effect of lorazepam depends on the covariate, and this dependence is the same 
across the levels of the challenge dose. When there was an association between one of the factors 
characterizing subjects’ lorazepam use and the drug’s effect on performance, we explored 
whether the association depended on age or gender by fitting models that included interactions 
with these demographic characteristics. An analogous strategy was used to evaluate whether (iv) 
baseline anxiety (measured by the Hamilton Anxiety scale) or (v) baseline depression (measured 
by Hamilton Depression scale) were related to how lorazepam affected memory and 
psychomotor performance.  
Statistical significance was set at α = 0.05, two-tailed. Following significant omnibus tests for 
  
overall differences, p-values for the post-hoc tests are reported without adjustment for multiple 
comparisons. For all exploratory analyses involving individual items on the self-report 
inventories that assessed mood states and anxiety levels and for the GAD subgroup analyses, we 
report significant effects, and indicate which effects remain statistically significant after control 
of False Discovery Rate (FDR). All analyses were performed using SAS® software. 
 
Results 
Of the 37 subjects meeting inclusion criteria, 31 completed all measures at all assessment 
points during both placebo and lorazepam sessions. Five of the six non-completing subjects were 
too physically and/or mentally fatigued to continue through to the fifth hour assessment, and the 
sixth withdrew after the 1st week. One subject was unable to complete tests of psychomotor 
performance due to neuropathy in the hands and wrists and was excluded from analyses of the 
PPT. Subject demographic and other characteristics assessed at screening are presented in Table 
1 for the full sample, and for both the study completers (n = 31), and non-completers (n = 6). All 
analyses included data from all 37 subjects in the study, when applicable. The subjects fell into 
the following SCID DSM-IV diagnoses: GAD, n=11; major depressive disorder (MDD), n=8; 
GAD and MDD, n=4; panic disorder, n=7; bipolar disorder, n=2; insomnia, n=4; adjustment 
disorder with anxiety, n=1. Finally, the 37 subjects had the following prescribed maximum unit 
lorazepam doses (which was their challenge dose): 0.25 mg, n=1; 0.50 mg, n=10; 1.00 mg, n=21; 
2.00 mg, n=4; 3.00 mg, n=1. 
 
  
Plasma Lorazepam Levels: 
Lorazepam levels could not be determined in six participants due to insufficient plasma. 
Results of the mixed model with repeated measures on available plasma lorazepam levels 
revealed a significant interaction effect of time and drug [F (3, 80) = 10.25, p < 0.001]. While 
subjects had detectable plasma lorazepam levels throughout the placebo condition as a 
consequence of long-term administration, levels were higher in the acute lorazepam challenge 
condition. Follow-up tests revealed significant increases in plasma lorazepam levels from 
baseline to 1 hour [7.86 ng/mL increase, Wald’s test z = 7.33, p <0.001] and then significant 
decreases from 1 hour to 2.5 hours [2.67 ng/mL decrease, z = -2.49, p = 0.015] under drug 
administration. There was no significant change in plasma lorazepam levels from baseline under 
placebo condition at any time.  
 
Figure 1. Total recall performance following an acute dose of lorazepam or placebo as a function 
of time (hours) following dose administration. Results represent group means and standard errors 
of the mean. 
 
 
 
  
Memory performance:  
Total recall scores are reported in Figure 1 and Table 2. The effect of lorazepam on Total 
Recall depended on time post drug administration. Compared to placebo, significant decline in 
total recall was evident at 1 and 2.5 hours. At 1 hour, the mean difference for lorazepam minus 
placebo was -3.82 items [SE=1.76, 95% CI (-7.32,-0.33), Cohen’s d=0.27], and at 2.5 hours, the 
mean difference was -5.16 items [SE=1.76, 95% CI (-8.65 -1.66), Cohen’s d=0.36].  
 
Table 2. Performance on memory and pegboard tests for lorazepam and placebo conditions at each study 
time point (BSRT = Buschke Selective Reminding Test; PPT = Purdue Pegboard Test). 
 
Outcome  Measure 
Hours 
Post 
Dose 
Mean (SD) 
Lorazepam Placebo 
BSRT Total 
1 46.95 (13.16) 50.08 (15.08) 
2.5 48.93 (13.07) 53.90 (12.94) 
5 52.67 (11.82) 54.39 (11.09) 
PPT 
Dominant Hand 
1 12.35 (1.98) 13.10 (1.93) 
2.5 12.70 (1.98) 13.23 (2.10) 
5 13.00 (2.09) 13.49 (1.96) 
PPT 
Non-Dominant Hand 
1 11.53 (2.12) 12.44 (2.02) 
2.5 11.83 (2.16) 12.33 (1.90) 
5 12.66 (2.10) 12.60 (2.05) 
PPT 
Both Hands 
1 9.65 (1.79) 10.10 (1.93) 
2.5 9.78 (1.82) 10.05 (2.01) 
5 9.91 (2.03) 10.40 (1.72) 
 
 
 
  
Psychomotor performance:  
Figure 2 and Table 2 show the three psychomotor performance measures based on PPT. 
The effect of lorazepam on dominant and non-dominant hand trials was a function of the time 
since lorazepam administration (F-tests for the interaction terms had p-values 0.008 and 0.035 
respectively). For the dominant hand the lorazepam-related slowing was significant at 1 and 2.5 
hours post-drug administration, but the effect sizes differed with the largest effect being present 
at 1 hour (Cohen’s d=0.44), and a smaller effect at 2.5 hours (d=0.28). Similarly, the results for 
the non-dominant hand showed significant slowing on lorazepam at 1 and 2.5 hours (d=0.41 and 
d=0.29, respectively), while at 5 hours the effect had disappeared. The effect of lorazepam on the 
PPT performance using both hands was not significant (p=0.13, d=0.20) with no relationship to 
time since drug administration. Total recall was not correlated with pegboard performance at any 
time point.  
 
 
Figure 2. Number of correctly inserted pegs using the dominant hand on the Purdue Pegboard 
Test following an acute dose of lorazepam or placebo as a function of time (hours) following 
dose administration. Results represent group means and standard errors of the mean. 
  
  
Subjective Feelings and differential effects:  
For the whole group, there was no effect of treatment at any time point on any of the 
MRS items. There was no effect of treatment on any of the 20 STAI-S items, except item #11 
"Self-confidence”, for which there was an interaction between treatment and time (p<0.001), 
indicating significant higher levels of self-confidence on lorazepam than on placebo at 2.5 hours 
[Wald’s test z = -2.77, p = 0.007, d = 0.64], and at 5 hours [z = -2.89, p = 0.005, d = 0.68]. The 
self-confidence ratings on lorazepam at this time point were not correlated with total recall or 
with dominant or non-dominant hand performance on the pegboard. 
Secondary analyses of subjects with GAD 
 A subgroup analysis was performed on the subjects with a diagnosis of GAD (n=11). 
With respect to memory and psychomotor performance, this subgroup’s response to lorazepam 
was similar to that found in the main analysis. However, with respect to mood, the self-ratings on 
the “Calm-Excited” question of the Mood Rating Scale (item #2) differed between drug 
administration and placebo, indicating a higher calmness rating while on lorazepam [at all time 
points, difference (lorazepam - placebo) mean = -5.81, SE=2.52, t (10) =-2.31, p = 0.044, d = 
1.46]. In addition, ratings on the “Troubled-Tranquil” question (item #8) were significantly 
higher on lorazepam than placebo, indicating a higher tranquility rating on lorazepam [at all time 
points, difference mean = 7.63, SE=3.30, t (10) = 2.32, p = 0.044, d = 1.46]. The STAI-S ratings 
on the “I feel at ease” question (item #5) on lorazepam were marginally higher at 2.5 hours 
(p=0.06), and  significantly lower at 5 hours [t (10) = 2.82, p = 0.009, d = 1.78] compared to 
placebo, indicating a subtle decline in this feeling in conjunction with lowering plasma drug 
  
levels. The ratings on the  STAI-S question “I feel pleasant” (item #20) on lorazepam were lower 
at 1 hour, but higher at 2.5 and 5 hours compared to placebo;  the change in this difference 
(lorazepam – placebo) from 1 to 2.5 hours was statistically significant, although the differences 
between lorazepam and placebo were not statistically significant at any time point.  None of the 
significant findings for this subgroup analyses survived the control of FDR. As with the analysis 
of the entire group, neither total recall nor pegboard performance were correlated with subjective 
reports of mood or affective states. 
 
Secondary analysis of the effects of total daily dose, dosing frequency, strength of challenge 
dose, and duration of treatment:   
The effect of lorazepam on Total Recall at 2.5 hours was not related to the total daily 
dose, dosing frequency, strength of challenge dose, or duration of treatment.  The effect of 
lorazepam on psychomotor performance measured by PPT dominant hand, non-dominant hand, 
and both hands did not depend on the dosing frequency. Lorazepam-related slowing on both 
dominant and non-dominant hands was associated with the  challenge dose: higher challenge 
doses were associated with greater slowing on lorazepam (2-way interaction (treatment)-by-
(challenge dose) p = 0.002 and 0.004, for dominant and non-dominant hand respectively). Total 
daily dose (which was highly correlated with the strength of the challenge dose, r=.71, p<0.01), 
did not have an effect on the lorazepam-related psychomotor slowing except on the dominant 
hand; the dependence was such that higher total daily doses were associated with less 
impairment due to lorazepam, controlling for the challenge dose (p=0.023).   
  
Controlling FDR, the only statistically significant results are those relating higher challenge 
doses to higher psychomotor impairment on dominant and non-dominant hands.  Age and gender 
did not modulate the effects of these factors.  
  
Secondary analyses of the effect of baseline anxiety and depression:  
The lorazepam effect on memory and motor performance did not depend on the level of 
anxiety at entry into the study, as measured by Ham-A.  Depression at the entry into the study 
(measured by Ham-D) was only related to the effect of lorazepam on the non-dominant hand 
performance, with more depressed subjects  performing more slowly  on lorazepam ((HamD)-
by-(treatment) interaction: F(1, 33)=7.99, p=0.008).  However, this finding did not survive 
control for FDR. 
 
General Discussion 
Despite long-term use of lorazepam, subjects continue to experience significant negative 
cognitive effects in the hours following oral administration of their prescribed unit dose. In 
several instances, these adverse effects lasted up to five hours post administration and were 
independent of age or gender.  
Our results of a significant impairment in total verbal recall in our sample of older individuals 
after acute challenge of their prescribed unit dose are consistent with previous studies in younger 
long-term benzodiazepine user populations, in which acute BZP challenge resulted in adverse 
memory deficits. In addition, as similar protocols were used, it is possible to compare our 
  
findings with one of our previous studies on the effects of lorazepam on memory in previously 
untreated elderly subjects (11). In the untreated group, declines in Total Recall under 1.0 mg of 
lorazepam compared to placebo at 1, 2.5, and 5 hours were 9.7%, 16.0%, and 9.1%, respectively, 
all of which were significant. In contrast, in this study, lorazepam induced declines in Total 
Recall by 6.3%, 9.2%, and 3.2% for the same time periods, with a significant effect at the 2.5 
hour time point. Though these sets of data were not from the same study, the comparison is made 
only to indicate the potential differences between lorazepam responses in long-term vs. drug 
naïve elderly subjects — while the negative effects of lorazepam on Total Recall are stronger for 
untreated participants, we still found negative effects on memory in the long-term treatment 
group. Because aging may be associated with some decline in memory, a further drug- induced 
impairment, as we have demonstrated, is more likely to result in clinically significant effects in 
this population. 
Furthermore, while tolerance has been most convincingly demonstrated for sedation and the 
adverse effects of BZPs on psychomotor performance, these observations have generally been 
derived from studies in younger populations on long-term treatment with BZPs (17).  Our results 
of significant impairment in psychomotor performance in an older population following an acute 
lorazepam challenge suggests that a complete tolerance to this adverse effect may not develop in 
this population, possibly contributing to the increased risk of falls and associated morbidity and 
mortality reported in older long term BZP community users. 
Self-ratings of anxiety, as measured by the total score on STAI-S, were not significantly reduced 
by acute lorazepam doses, and it should be noted that all long-term users still exhibited 
  
significant residual symptoms of anxiety at baseline. This is in contrast to previous studies on 
younger populations, which have reported little to no tolerance developed towards anxiolytic 
activity in long-term BZP user populations (5, 32), suggesting that anxiolytic efficacy may 
decline after long-term lorazepam treatment in older populations. Total recall and pegboard 
performance were neither correlated with each other nor with self-ratings of mood states and 
anxiety levels at any time point following lorazepam administration, implying that the declines in 
memory and psychomotor performance associated with acute lorazepam challenge in long-term 
users are not accompanied by changes in self-ratings of mood states, including increased 
sedation.  Thus, while the therapeutic benefits of lorazepam may fade with long-term use, the 
adverse effects on memory and psychomotor performance appear to persist. 
However, in further exploratory analyses, we found that the subgroup of individuals with a GAD 
diagnosis did experience a significant therapeutic anxiolytic effect. Although these observations 
were the result of secondary analyses with relatively small sample sizes, they do raise the 
possibility of a mechanistic interpretation. The pharmacodynamic action of BZPs, including 
lorazepam, is in part related to benzodiazepine receptor densities, the concentration of 
presynaptically-released GABA, and an enhancement of post-synaptic ionotropic GABA-A 
receptor-mediated inhibitory currents (e.g., 33, 34). Tolerance development after chronic 
benzodiazepine administration has been associated with reductions in benzodiapzine receptor 
densities, region and GABA-A receptor subtype specific reductions in both GABA-A receptor 
density and function (35, 36, 37), as well as changes in ionotropic glutamate receptors , as well 
as other neurotransmitters and the neurosteroid system (38). The aforementioned results of 
  
impairment in memory and psychomotor performance, along with the continued therapeutic 
effects seen in the GAD population after acute lorazepam challenges are not consistent with a 
significant down regulation of BZP receptor density and GABA-A receptor function in the 
specific brain circuits mediating these effects in this population of long-term lorazepam users 
(22). Therefore, future studies, including in vivo magnetic resonance spectroscopy neuro-
imaging and other techniques, should be considered to elucidate the status of central 
benzodiazepine receptor density and GABA-A receptor function in long-term elderly users, and 
the degree to which possible receptor abnormalities associated with disorders such as GAD, 
MDD, panic disorder, and insomnia might influence anxiolytic BZP response and tolerance 
development.  
Finally, our results suggest that the decline in memory performance induced by an acute 
lorazepam challenge can reflect changes in central nervous system function that, while triggered 
by the drug, continue to worsen while plasma drug levels are already subsiding. The impact on 
psychomotor slowing, in which the magnitude of the effect was related to the time course of the 
plasma drug levels, is different than that on memory, which may reflect a form of short-term 
pharmacodynamic plasticity that has the potential to last for hours and be influenced by genetic 
factors (11). Both the memory and psychomotor declines following lorazepam challenge contrast 
with the psychological effects in GAD, where self-ratings of calmness and tranquility were 
elevated across time points. The temporal characteristics of cognitive toxicity, which may be 
unlike other effects of BZPs, warrant further study, and the temporal differences in lorazepam’s 
impact on memory, psychomotor function, and mood in long-term users not only has clinical 
  
relevance, but may lead to a better understanding of the differential effects of BZPs on different 
neurobiological systems.   
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